NVCR - NovoCure GAAP EPS of -$0.23 misses by $0.09 revenue of $140.9M beats by $5.77M
- NovoCure press release ( NASDAQ: NVCR ): Q2 GAAP EPS of -$0.23 misses by $0.09 .
- Revenue of $140.9M (+5.5% Y/Y) beats by $5.77M .
- Shares -1.9% PM.
- As of June 30, 2022, there were 3,454 active patients on therapy. Active patients from North America, EMEA and Japan contributed 2,229, 879 and 346 active patients, respectively.
- 1,383 prescriptions were received in the quarter. Prescriptions from North America, EMEA and Japan contributed 954, 334 and 95 prescriptions, respectively.
For further details see:
NovoCure GAAP EPS of -$0.23 misses by $0.09, revenue of $140.9M beats by $5.77M